In isocitrate dehydrogenase 1 (IDH1)-mutant Acute Myeloid Leukemia (AML), the combination of Ivosidenib with the hypomethylating agent azacitidine, significantly improved clinical outcomes compared to monotherapy. Here, IDH1 is linked to acute myeloid leukemia.